Dechra Pharmaceuticals to Acquire Invetx
July 18, 2024
Dechra Pharmaceuticals Limited has agreed to acquire Boston-based Invetx Inc., a developer of species-specific monoclonal antibody therapeutics for companion animals, for up to $520 million on a cash-free, debt-free basis, subject to customary approvals. The deal gives Dechra access to Invetx's pipeline and half-life extension platform to expand its specialty veterinary biologics capabilities.
- Buyers
- Dechra Pharmaceuticals Limited
- Targets
- Invetx Inc.
- Sellers
- Novo Holdings A/S, F-Prime Capital, GV, Eight Roads, Anterra Capital, Casdin Capital, Tekla Capital Management
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Innova Therapeutics Acquires Enci Therapeutics
November 27, 2025
Biotechnology
Innova Therapeutics has completed the acquisition of Enci Therapeutics, adding Enci’s lead oncology program, IVT-8086, a first-in-class humanized monoclonal antibody targeting SFRP2, to its development pipeline. Financial terms were not disclosed; Innova said the program and associated IP (patents through at least 2042) will support development across multiple solid and hematologic cancers and a companion diagnostic is in development.
-
IMV Technologies Acquires UD-Vet B.V.
September 26, 2024
Veterinary
French animal health equipment maker IMV Technologies has acquired UD-Vet B.V., a Benelux-based provider of veterinary practice equipment and imaging solutions. The deal brings UD-Vet's team and product/service offering into IMV's Companion Animal business to consolidate and expand IMV's presence in the Benelux region.
-
Novartis Acquires DTx Pharma
July 17, 2023
Biotechnology
Novartis has acquired DTx Pharma, a San Diego–based preclinical biotechnology company, for an upfront payment of USD 500 million plus contingent milestone payments. The deal brings DTx's FALCON siRNA delivery platform and lead program DTx-1252 (orphan-designated for CMT1A) into Novartis to strengthen its neuroscience pipeline and xRNA capabilities.
-
Freya Bidco (EQT & ADIA) Acquires Dechra Pharmaceuticals plc
June 2, 2023
Pharmaceuticals
Freya Bidco Limited, an acquisition vehicle indirectly owned by EQT Private Equity and Luxinva S.A. (a wholly owned subsidiary of the Abu Dhabi Investment Authority), reached a recommended cash acquisition of UK‑listed Dechra Pharmaceuticals plc, valued at approximately GBP 4.459 billion (3,875 pence per share). The scheme was approved by the requisite majority of Dechra shareholders; EQT said it will support Dechra’s next phase of growth by investing in its veterinary pharmaceuticals pipeline and furthering global expansion.
-
Dechra Pharmaceuticals Acquires Med-Pharmex from DW Healthcare Partners
August 30, 2022
Veterinary
Dechra Pharmaceuticals PLC has completed the acquisition of Med-Pharmex Holdings, Inc. from DW Healthcare Partners. The deal brings a US-based, fully integrated veterinary pharmaceutical manufacturer (Med-Pharmex) into Dechra's global animal-health platform to strengthen its manufacturing capabilities and North American footprint.
-
Amgen Acquires ChemoCentryx
August 4, 2022
Biotechnology
Amgen agreed to acquire ChemoCentryx for $52 per share in cash (approximately $3.7 billion enterprise value), gaining TAVNEOS (avacopan), a first-in-class oral therapy for ANCA-associated vasculitis. The deal, unanimously approved by both boards, is intended to strengthen Amgen's inflammation and nephrology portfolio and is expected to close following stockholder and regulatory approvals.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.